Adverum Biotechnologies Announces Proposed Public Offering of Common Stock
Adverum Biotechnologies, Inc. (ADVM)
Last adverum biotechnologies, inc. earnings: 3/12 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
adverum.gcs-web.com/investor-overview
Company Research
Source: GlobeNewswire
MENLO PARK, Calif., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, today announced that it has commenced an underwritten public offering of its common stock. The company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. All of the shares in the offering will be sold by Adverum Biotechnologies. The offering is subject to market and other conditions, and there can be no assurances as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Cowen and Piper Jaffray & Co. are acting as joint book-running managers for the proposed offering. Raymond James is acting as lead manager. The shares described above are being offered by Adverum Biotechnologies pursuant to a shelf registration statement on Form S-3 t
Show less
Read more
Impact Snapshot
Event Time:
ADVM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADVM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADVM alerts
High impacting Adverum Biotechnologies, Inc. news events
Weekly update
A roundup of the hottest topics
ADVM
News
- Down -29.25% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM) [Yahoo! Finance]Yahoo! Finance
- Adverum Biotechnologies, Inc. (NASDAQ: ADVM) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- US Retinal Specialists Highlight the Greatest Opportunity for Gene Therapies [Yahoo! Finance]Yahoo! Finance
- Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year? [Yahoo! Finance]Yahoo! Finance
- Adverum Biotechnologies, Inc. (NASDAQ: ADVM) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $4.00 price target on the stock.MarketBeat
ADVM
Earnings
- 11/9/23 - Miss
ADVM
Sec Filings
- 3/27/24 - Form EFFECT
- 3/21/24 - Form S-3
- 3/18/24 - Form S-8
- ADVM's page on the SEC website